Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
RMTI's Cash-to-Debt is ranked higher than
99% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RMTI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 27.81 Max: No Debt
Current: No Debt
Equity-to-Asset 0.64
RMTI's Equity-to-Asset is ranked higher than
54% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. RMTI: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
RMTI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.59  Med: 0.63 Max: 0.87
Current: 0.64
-0.59
0.87
Interest Coverage No Debt
RMTI's Interest Coverage is ranked higher than
98% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.29 vs. RMTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RMTI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 3.44
Beneish M-Score: -2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -37.92
RMTI's Operating Margin % is ranked lower than
83% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.86 vs. RMTI: -37.92 )
Ranked among companies with meaningful Operating Margin % only.
RMTI' s Operating Margin % Range Over the Past 10 Years
Min: -108.87  Med: -29.84 Max: -4.82
Current: -37.92
-108.87
-4.82
Net Margin % -37.16
RMTI's Net Margin % is ranked lower than
84% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. RMTI: -37.16 )
Ranked among companies with meaningful Net Margin % only.
RMTI' s Net Margin % Range Over the Past 10 Years
Min: -108.39  Med: -31.61 Max: -4.51
Current: -37.16
-108.39
-4.51
ROE % -34.28
RMTI's ROE % is ranked lower than
83% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.66 vs. RMTI: -34.28 )
Ranked among companies with meaningful ROE % only.
RMTI' s ROE % Range Over the Past 10 Years
Min: -1304.41  Med: -34.36 Max: -8.96
Current: -34.28
-1304.41
-8.96
ROA % -23.02
RMTI's ROA % is ranked lower than
82% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.48 vs. RMTI: -23.02 )
Ranked among companies with meaningful ROA % only.
RMTI' s ROA % Range Over the Past 10 Years
Min: -220.66  Med: -27.46 Max: -7.47
Current: -23.02
-220.66
-7.47
ROC (Joel Greenblatt) % -170.68
RMTI's ROC (Joel Greenblatt) % is ranked lower than
85% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.44 vs. RMTI: -170.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RMTI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2678.13  Med: -260.69 Max: -52.63
Current: -170.68
-2678.13
-52.63
3-Year Revenue Growth Rate -12.90
RMTI's 3-Year Revenue Growth Rate is ranked lower than
87% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. RMTI: -12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RMTI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -23.2  Med: 2.7 Max: 32
Current: -12.9
-23.2
32
3-Year EBITDA Growth Rate -35.90
RMTI's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.70 vs. RMTI: -35.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RMTI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.9  Med: -24.2 Max: 165.1
Current: -35.9
-52.9
165.1
3-Year EPS without NRI Growth Rate -35.90
RMTI's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. RMTI: -35.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RMTI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -20.6 Max: 109.9
Current: -35.9
0
109.9
GuruFocus has detected 4 Warning Signs with Rockwell Medical Inc $RMTI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RMTI's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

RMTI Guru Trades in

Q2 2015

RMTI Guru Trades in Q2 2015

Paul Tudor Jones 26,035 sh (+3.44%)
» More
Q3 2015

RMTI Guru Trades in Q3 2015

Paul Tudor Jones 49,916 sh (+91.73%)
» More
Q4 2015

RMTI Guru Trades in Q4 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NAS:NBRV, NAS:ZGNX, NAS:ASMB, NAS:ALIM, OTCPK:FAMDF, OTCPK:BIOYF, AMEX:NNVC, NAS:OASM, NAS:PRPH, AMEX:AXN, NAS:NVGN, NAS:IMNP, OTCPK:SUWN, NAS:TNXP, NAS:ALQA, OTCPK:INNV, AMEX:CPHI, NAS:BSPM, OTCPK:INBP, OTCPK:ECTE » details
Traded in other countries:RWM.Germany,
Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.

Ratios

vs
industry
vs
history
PB Ratio 5.89
RMTI's PB Ratio is ranked lower than
77% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.93 vs. RMTI: 5.89 )
Ranked among companies with meaningful PB Ratio only.
RMTI' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 7.33 Max: 950
Current: 5.89
1.73
950
PS Ratio 5.76
RMTI's PS Ratio is ranked lower than
71% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. RMTI: 5.76 )
Ranked among companies with meaningful PS Ratio only.
RMTI' s PS Ratio Range Over the Past 10 Years
Min: 0.47  Med: 2.73 Max: 14.67
Current: 5.76
0.47
14.67
EV-to-EBIT -12.93
RMTI's EV-to-EBIT is ranked lower than
99.99% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. RMTI: -12.93 )
Ranked among companies with meaningful EV-to-EBIT only.
RMTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -1985.5  Med: -15.1 Max: -1.2
Current: -12.93
-1985.5
-1.2
EV-to-EBITDA -13.46
RMTI's EV-to-EBITDA is ranked lower than
99.99% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.30 vs. RMTI: -13.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
RMTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1117.1  Med: -16.55 Max: 102.9
Current: -13.46
-1117.1
102.9
Current Ratio 7.74
RMTI's Current Ratio is ranked higher than
88% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. RMTI: 7.74 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.96 Max: 10.46
Current: 7.74
0.49
10.46
Quick Ratio 6.54
RMTI's Quick Ratio is ranked higher than
88% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.73 vs. RMTI: 6.54 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.61 Max: 9.49
Current: 6.54
0.35
9.49
Days Inventory 81.50
RMTI's Days Inventory is ranked higher than
68% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. RMTI: 81.50 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s Days Inventory Range Over the Past 10 Years
Min: 21.24  Med: 23.36 Max: 81.5
Current: 81.5
21.24
81.5
Days Sales Outstanding 43.79
RMTI's Days Sales Outstanding is ranked higher than
80% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.23 vs. RMTI: 43.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.3  Med: 32.18 Max: 43.79
Current: 43.79
23.3
43.79
Days Payable 45.95
RMTI's Days Payable is ranked lower than
74% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. RMTI: 45.95 )
Ranked among companies with meaningful Days Payable only.
RMTI' s Days Payable Range Over the Past 10 Years
Min: 26.41  Med: 40.52 Max: 125.48
Current: 45.95
26.41
125.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.70
RMTI's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 441 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. RMTI: -8.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RMTI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -39  Med: -14.4 Max: 9.6
Current: -8.7
-39
9.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.20
RMTI's Price-to-Net-Cash is ranked lower than
53% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.69 vs. RMTI: 11.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RMTI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.54  Med: 11.64 Max: 71
Current: 11.2
7.54
71
Price-to-Net-Current-Asset-Value 6.44
RMTI's Price-to-Net-Current-Asset-Value is ranked higher than
57% of the 486 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. RMTI: 6.44 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RMTI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.27  Med: 7.91 Max: 19.19
Current: 6.44
5.27
19.19
Price-to-Tangible-Book 5.99
RMTI's Price-to-Tangible-Book is ranked lower than
68% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. RMTI: 5.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RMTI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.59  Med: 6.49 Max: 25.25
Current: 5.99
3.59
25.25
Price-to-Median-PS-Value 2.11
RMTI's Price-to-Median-PS-Value is ranked lower than
82% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. RMTI: 2.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RMTI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.85 Max: 3.39
Current: 2.11
0.15
3.39
Earnings Yield (Greenblatt) % -7.73
RMTI's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. RMTI: -7.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RMTI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.7  Med: 0.7 Max: 0.7
Current: -7.73
-9.7
0.7

More Statistics

Revenue (TTM) (Mil) $53.29
EPS (TTM) $ -0.40
Beta2.08
Short Percentage of Float18.36%
52-Week Range $3.55 - 10.58
Shares Outstanding (Mil)51.53

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 61 69 72
EPS ($) -0.20 -0.05 0.03
EPS without NRI ($) -0.20 -0.05 0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 
Rockwell Medical Technologies Inc. (RMTI) Vice President, CFO Thomas E Klema sells 15,000 Shares Jan 03 2011 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 07 2010 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 06 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 10 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ROCKWELL MEDICAL, INC. Financials Mar 24 2017
Richmond Brothers and Mark Ravich Comment on Rockwell Medical, Inc. Lawsuit Mar 22 2017
Rockwell Medical, Inc. :RMTI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Rockwell Medical, Inc. :RMTI-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017 Mar 17 2017
Rockwell Medical, Inc. breached its 50 day moving average in a Bullish Manner : RMTI-US : March 17,... Mar 17 2017
Richmond Brothers and Mark Ravich Comment on Rockwell Medical, Inc. Earnings Mar 16 2017
Edited Transcript of RMTI earnings conference call or presentation 15-Mar-17 8:30pm GMT Mar 15 2017
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 15 2017
Rockwell Medical reports 4Q loss Mar 15 2017
Rockwell Medical reports 4Q loss Mar 15 2017
Rockwell Medical Reports Fourth Quarter Results Mar 15 2017
Q4 2016 Rockwell Medical Inc Earnings Release - After Market Close Mar 15 2017
Rockwell Medical Schedules Fourth Quarter & Year End 2016 Earnings Call Mar 13 2017
Richmond Brothers and Mark Ravich Respond to Rockwell Medical, Inc. Lawsuit Mar 09 2017
Rockwell Medical Announces One Poster and Two Oral Presentations on Triferic at Annual Dialysis... Mar 06 2017
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Mar 03 2017
Rockwell Medical shareholders nominate two directors in proxy fight Mar 02 2017
Richmond Brothers and Mark Ravich Announce Nomination of Two Highly-Qualified Candidates for Board... Mar 02 2017
Rockwell Medical shareholders launch proxy fight, nominate two directors Mar 02 2017
Rockwell Medical Announces Nomination of David Domzalski to Board of Directors Mar 02 2017
Rockwell Medical Updates Progress on Calcitriol Commercial Launch Feb 21 2017
Rockwell Medical will Present Data on Triferic Intravenous (IV) Administration at the 19th... Jan 26 2017
Implied Volatility Surging for Rockwell Medical (RMTI) Stock Options Jan 25 2017
Rockwell Medical Reports Third Quarter Results Nov 07 2016
Rockwell Medical Schedules Third Quarter 2016 Earnings Call Nov 03 2016
Rockwell Medical Announces Triferic Human Intravenous (IV) Pharmacokinetic Study Published in... Oct 04 2016
Rockwell Medical Preparing for Calcitriol Commercial Launch Sep 22 2016
Rockwell Medical Enters into Exclusive License Agreement with ARAM Medical to Commercialize... Aug 16 2016
Rockwell Medical Reports Second Quarter Results Aug 08 2016
Rockwell Medical Schedules Second Quarter 2016 Earnings Call Aug 03 2016
Rockwell Medical Announces Appointment of Dr. Robin Smith to Board of Directors Jun 23 2016
Rockwell Medical Announces Multiple International Trademark Approvals for Triferic® May 12 2016
Rockwell Medical Reports First Quarter Results May 10 2016
Rockwell Medical Schedules First Quarter 2016 Earnings Call May 05 2016
Rockwell Medical Provides Update on Preparations for Calcitriol Commercial Launch May 04 2016
Rockwell Medical Announces Triferic® Presentation "Overcoming Functional Iron Deficiency in Your... Apr 28 2016
U.S. FDA Approves Rockwell's Triferic® Powder Packet for Treating Anemia in Hemodialysis Patients Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)